Stocks Health care TMCI
NASDAQ · Health careTreace Medical Concepts, Inc. (TMCI)
Treace Medical Concepts, Inc. brought in $203.3M of revenue over the twelve months to September 30, 2026, down 7.1% from a year earlier. It posted a net loss of $55.8M. In fiscal 2025 capital spending exceeded operating cash flow by $29.5M. At September 30, 2026 it held $7.8M in cash against $56.3M of debt. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on November 6, 2026.
Key facts about Treace Medical Concepts, Inc.
- Net worth
- Treace Medical Concepts, Inc. has a market value (market cap) of $310.9M at the latest share price, and shareholders' equity of $61.6M on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Revenue and profit
- In fiscal 2025 revenue was $212.7M (+1.6% year on year), with a net loss of $59M. Over the 12 months to September 30, 2026: revenue $203.3M, net loss $55.8M.
- Cash flow
- In fiscal 2025 operations used $16M of cash.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on November 6, 2026 and covers the period to September 30, 2026. Open on SEC EDGAR
- Next earnings report
- Treace Medical Concepts, Inc.'s next report is expected around January 12, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
What Treace Medical Concepts, Inc. does
Treace Medical Concepts, Inc. is registered with the SEC under industry code SIC 3841 (Surgical & Medical Instruments & Apparatus). Its shares trade on NASDAQ under the ticker TMCI.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $212.7M | -$59M | -$0.93 | -$29.5M |
| 2024 | $209.4M | -$55.7M | -$0.90 | -$48.8M |
| 2023 | $187.1M | -$49.5M | -$0.81 | -$46M |
| 2022 | $141.8M | -$42.8M | -$0.77 | -$45.5M |
| 2021 | $94.4M | -$20.6M | -$0.43 | -$19.9M |
| 2021 | $57.4M | -$3.7M | -$0.12 | -$5.6M |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Where TMCI ranks in Health care
Latest SEC filings
What Treace Medical Concepts, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- November 6, 2026Quarterly report 10-Q · period to September 30, 2026Revenue fell 3.9% to $48.3M versus the same quarter last year; diluted EPS -$0.19 versus -$0.26.
- November 6, 2026
- August 14, 2026Passive stake changed SCHEDULE 13G/A
- August 12, 2026Passive stake changed SCHEDULE 13G/A
- August 7, 2026Quarterly report 10-Q · period to June 30, 2026Revenue fell 4.2% to $45.4M versus the same quarter last year; diluted EPS -$0.24 versus -$0.28.
- August 7, 2026
- July 30, 2026Passive stake changed SCHEDULE 13G/A
- May 20, 2026
- May 15, 2026Passive stake changed SCHEDULE 13G/A
- May 14, 2026Passive stake (5% or more) SCHEDULE 13G
Insider trades
What the people running Treace Medical Concepts, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
Insiders bought $246.7K worth of shares on the open market in the last 90 days and sold none.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| October 24, 2026 | Scanlan Sean F.Chief Innovation Officer | Shares withheld for tax | 207 | - |
| September 30, 2026 | Elder Scot MichaelChief Legl & Comp Off, CorpSec | Shares withheld for tax | 25,457 | - |
| August 24, 2026 | Treace John T.Chief Executive Officer, Director, 10% owner | Bought | 11,000 | $47.7K |
| August 21, 2026 | Treace John T.Chief Executive Officer, Director, 10% owner | Bought | 5,000 | $21.7K |
| August 20, 2026 | Treace John T.Chief Executive Officer, Director, 10% owner | Bought | 39,944 | $177.2K |
| August 9, 2026 | Elder Scot MichaelChief Legl & Comp Off, CorpSec | Shares withheld for tax | 16,253 | - |
| August 9, 2026 | Hair MarkChief Financial Officer | Shares withheld for tax | 37,102 | - |
| August 9, 2026 | Scanlan Sean F.Chief Innovation Officer | Shares withheld for tax | 9,814 | - |
Who owns TMCI
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| John T. Treace13G, passive | 19.2% | August 12, 2026 |
| Armistice Capital, LLC13G, passive with 1 related filers | 9.79% | August 14, 2026 |
| Neil Gagnon13G, passive with 2 related filers | 9.6% | February 12, 2026 |
Largest institutional holders
Positions that investment managers reported on Form 13F for the quarter ended June 30, 2026, largest first, with the change on the quarter ended March 31, 2026. Managers file 13F up to 45 days after a quarter ends. 117 managers reported a position.
| Holder | Shares | Change on quarter |
|---|---|---|
| Armistice Capital, LLC | 6,364,000 | 0 |
| Bank of America Corp | 3,305,100 | +90,807 |
| Gagnon Securities LLC | 3,029,543 | -2,172,343 |
| Vanguard Capital Management LLC | 2,028,479 | +566,972 |
| Gagnon Advisors, LLC | 1,534,034 | new |
| Aqr Capital Management LLC | 1,497,673 | +435,833 |
| BlackRock, Inc. | 1,380,021 | -1,960,002 |
| Marshall Wace, Llp | 1,328,592 | +1,063,659 |
| CIBC Bancorp USA Inc. | 1,216,044 | -2,309 |
| Millennium Management LLC | 738,628 | -409,487 |
| Weber Capital Management LLC | 589,617 | 0 |
| D. E. Shaw & Co., Inc. | 583,277 | -257,992 |
| Geode Capital Management, LLC | 573,796 | -437,047 |
| Citadel Advisors LLC | 516,994 | -308,581 |
| Goldman Sachs Group Inc | 492,116 | +104,431 |
| Stifel Financial Corp | 435,009 | +258,917 |
| UBS Group AG | 366,445 | -176,460 |
| Jacobs Levy Equity Management, Inc | 363,729 | +99,995 |
| Raymond James Financial Inc | 331,110 | -26,446 |
| Morgan Stanley | 320,026 | +100,319 |
Insiders
11 insiders reported holding 10,820,206 shares in total, about $51.7M at the last price.
| Holder | Shares |
|---|---|
| Treace John T.Chief Executive Officer, Director, 10% owner | 7,404,383 |
| Hair MarkChief Financial Officer | 914,900 |
| Elder Scot MichaelChief Legl & Comp Off, CorpSec | 753,226 |
| Scanlan Sean F.Chief Innovation Officer | 634,656 |
| Guglielmino GaetanoChief Commercial Officer | 490,901 |
| Bakewell John KDirector | 204,056 |
| Jain DeeptiDirector | 100,243 |
| Kiernan Jane EDirector | 93,949 |
| Hanna BetsyDirector | 75,243 |
| Berry Lance ADirector | 74,593 |
Questions about TMCI
What does Treace Medical Concepts, Inc. do?
Treace Medical Concepts, Inc. is a company in the Health care sector, listed on NASDAQ as TMCI. Its shares trade on NASDAQ under the ticker TMCI.
What is Treace Medical Concepts, Inc.'s net worth?
Treace Medical Concepts, Inc. has a market value (market cap) of $310.9M at the latest share price, and shareholders' equity of $61.6M on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Treace Medical Concepts, Inc. profitable?
No. Over the twelve months to September 30, 2026 it reported a net loss of $55.8M on revenue of $203.3M.
How much revenue does Treace Medical Concepts, Inc. make?
Over the twelve months to September 30, 2026 Treace Medical Concepts, Inc. reported revenue of $203.3M. That is 7.1% less than a year earlier.
When did Treace Medical Concepts, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on November 6, 2026. It covers the period to September 30, 2026.
When is Treace Medical Concepts, Inc.'s next earnings report?
Treace Medical Concepts, Inc.'s next report is expected around January 12, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
Similar companies
Compare TMCI with
Follow TMCI
Get an email when Treace Medical Concepts, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Treace Medical Concepts, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.